These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27232589)

  • 1. Investigational drugs for treating agitation in persons with dementia.
    Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
    Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
    Garay RP; Grossberg GT
    Expert Opin Investig Drugs; 2017 Jan; 26(1):121-132. PubMed ID: 27936965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational drugs in recent clinical trials for treatment-resistant depression.
    Garay RP; Zarate CA; Charpeaud T; Citrome L; Correll CU; Hameg A; Llorca PM
    Expert Rev Neurother; 2017 Jun; 17(6):593-609. PubMed ID: 28092469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.
    Ward K; Citrome L
    Expert Opin Investig Drugs; 2022 Aug; 31(8):773-780. PubMed ID: 35763451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
    Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
    Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
    Kongpakwattana K; Sawangjit R; Tawankanjanachot I; Bell JS; Hilmer SN; Chaiyakunapruk N
    Br J Clin Pharmacol; 2018 Jul; 84(7):1445-1456. PubMed ID: 29637593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    J Am Med Dir Assoc; 2024 Oct; 25(10):105173. PubMed ID: 39053890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
    Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
    Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.
    Zhong K; Cummings J
    Expert Rev Neurother; 2024 Sep; ():1-9. PubMed ID: 39344050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia.
    Postgrad Med; 1998 Apr; Spec No():1-88. PubMed ID: 9585819
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
    [No Abstract]   [Full Text] [Related]  

  • 17. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
    Aga VM
    Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.
    Ward K; Citrome L
    Expert Opin Investig Drugs; 2020 Mar; 29(3):245-257. PubMed ID: 32031021
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.